| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/JMRI.1224 |
| P698 | PubMed publication ID | 11747012 |
| P2093 | author name string | V Smyrniotis | |
| A D Gouliamos | |||
| L J Vlahos | |||
| D T Kehagias | |||
| P2860 | cites work | Hepatic lesion detection and characterization: value of nonenhanced MR imaging, superparamagnetic iron oxide-enhanced MR imaging, and spiral CT-ROC analysis. | Q34049777 |
| Hepatic lesion detection after superparamagnetic iron oxide enhancement: comparison of five T2-weighted sequences at 1.0 T by using alternative-free response receiver operating characteristic analysis. | Q52864606 | ||
| Superparamagnetic iron oxide particles (SH U 555 A): evaluation of efficacy in three doses for hepatic MR imaging. | Q52997053 | ||
| Liver metastases: improved detection with dynamic gadolinium-enhanced MR imaging? | Q53001263 | ||
| Hepatic MR imaging with ferumoxides: a multicenter clinical trial of the safety and efficacy in the detection of focal hepatic lesions. | Q54004869 | ||
| Focal liver disease: comparison of dynamic contrast-enhanced CT and T2-weighted fat-suppressed, FLASH, and dynamic gadolinium-enhanced MR imaging at 1.5 T | Q67495087 | ||
| Hepatocellular tumors: characterization with Mn-DPDP-enhanced MR imaging | Q70460020 | ||
| Liver masses: replacement of conventional T2-weighted spin-echo MR imaging with breath-hold MR imaging | Q71204260 | ||
| Results of a multicenter phase II clinical trial with a susceptibility contrast medium for magnetic resonance imaging of the liver | Q71511006 | ||
| Magnetic resonance imaging of focal liver lesions. Comparison of the superparamagnetic iron oxide resovist versus gadolinium-DTPA in the same patient | Q71773533 | ||
| Superparamagnetic iron oxide: detection of focal liver lesions at high-field-strength MR imaging | Q72131186 | ||
| Clinical results with Resovist: a phase 2 clinical trial | Q72176318 | ||
| Liver metastases: safety and efficacy of detection with superparamagnetic iron oxide in MR imaging | Q72837156 | ||
| Contrast-enhanced MR imaging of liver and spleen: first experience in humans with a new superparamagnetic iron oxide | Q72860120 | ||
| MR imaging of the liver with Resovist: safety, efficacy, and pharmacodynamic properties | Q73656295 | ||
| Detection of focal hepatic lesions: comparison of unenhanced and SHU 555 A-enhanced MR imaging versus biphasic helical CTAP | Q73912587 | ||
| P433 | issue | 5 | |
| P304 | page(s) | 595-601 | |
| P577 | publication date | 2001-11-01 | |
| P1433 | published in | Journal of Magnetic Resonance Imaging | Q15761156 |
| P1476 | title | Diagnostic efficacy and safety of MRI of the liver with superparamagnetic iron oxide particles (SH U 555 A) | |
| P478 | volume | 14 |
| Q46364711 | Comparison of MRI (including SS SE-EPI and SPIO-enhanced MRI) and FDG-PET/CT for the detection of colorectal liver metastases |
| Q36963721 | Contrast agents for hepatic MRI. |
| Q30472127 | Exogenous Molecular Probes for Targeted Imaging in Cancer: Focus on Multi-modal Imaging |
| Q36125208 | Molecular probes for the in vivo imaging of cancer |
| Q35997318 | Safety of MR liver specific contrast media |
| Q59312613 | Targeted Nanoparticle Binding to Hydroxyapatite in a High Serum Environment for Early Detection of Heart Disease |
Search more.